Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the marketing authoriz...
CLNY , CORE , EBIX , FL , KOP , NWN , PEGI , PTLA , SNH , SSP , STRA , TGNA , TRCO , WUBA , XRAY For Seeking Alpha's full earnings season calendar, click here . More news on: Colony Capital, Inc., Core-Mark Holding Company, Inc., Ebix Inc, Earnings news and commentary,...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Once again U.S.-China trade talks will be watched closely as reports filter in on a...
Noteworthy events during the week of February 24 - March 2 for healthcare investors. More news on: uniQure N.V., Bausch Health Companies Inc., CytomX Therapeutics, Healthcare stocks news, , Read more ...
– Excellent or Good Hemostasis Achieved in 82 Percent of Evaluable Patients – –Thrombotic Event Rate of 9.7 Percent Across All Patients, No Thrombotic Events Observed Among Patients Who Re-started Oral Anticoagulation Therapy – – Data Present...
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter and full year ended December 31, 2018, and pr...
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that full results from the Company’s ANNEXA-4 study of Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo] have been accepted as a l...
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced the appointment of Sheldon Koenig as executive vice president and chief commercial officer, effective immediately. Mr. Koenig brings to his new role more than ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Like action? What a week ahead with a cavalcade of companies due to present across ...
News, Short Squeeze, Breakout and More Instantly...
Portola Pharmaceuticals Inc. Company Name:
PTLA Stock Symbol:
NASDAQ Market:
Portola Pharmaceuticals Inc. Website:
SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and othe...
SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ® [coagula...
SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to continue to su...